TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
Table 1
Baseline of patients with CHB in NA-naïve and NA-experienced group, respectively.
TDF NA-naïve
TDF NA-experienced
Statistics
()
()
Age (years)
35 (26–61)
34.0 (24–61)
0.128
Sex (male, %)
72.2 (26/36)
71.2 (47/66)
0.914
Body mass index (kg/m2)
22.63 ± 2.73
23.85 ± 2.86
0.723
Follow-up time (weeks)
42.0 (25.0–109.0)
55.5 (24.0–110.0)
0.199
The proportion of alcohol history (%)
22.2 (8/36)
25.8 (17/66)
0.692
The proportion of smoking history (%)
38.9 (14/36)
21.2 (14/66)
0.056
Family history of hepatitis B (%)
58.3 (21/36)
48.5 (32/66)
0.341
ALT baseline (U/L)
136.0 (56–597)
80 (10–1231)
0.786
HBV DNA baseline (log10 IU/ml)
6.50 ± 0.69
5.78 ± 1.49
0.054
NA-experienced (%) previously
N/A
LMV (%)
6.06 (4/66)
ADV (%)
1.51 (1/66)
LdT (%)
9.09 (6/66)
ETV (%)
10.6 (7/66)
Complicated# (%)
72.7 (48/66)
Rate of hepatitis B e antigen positive (%)
50.0 (18/36)
53.0 (35/66)
0.770
ALT: alanine aminotransferase; TDF: tenofovir disoproxil fumarate; NA: nucleos(t)ide analogue. N/A: not applicable. LMV: lamivudine, LdT: telbivudine, ADV: adefovir dipivoxil, and ETV: entecavir. #Complicated experience means at least two or more than two different NAs before switching to TDF.
Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.
